Supriya Lifescience Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Supriya Lifescience Share Price

977.1540.15 (4.29%)

Closed
As On: 12 Jun, 2026, 03:56 PM IST
As On: 12 Jun, 2026, 03:40 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	960.00
High	995.00
Low	952.55
Prev Close	937.00
Volume	7,09,530
VWAP(₹)	981.37

Key Metrics

PE Ratio(x)	37.61
EPS - TTM(₹)	25.98
MCap(₹ Cr.)	7,864.38
MCap Rank	52
PB Ratio(x)	6.40
Div Yield(%)	-
Face Value(₹)	2.00
52W High(₹)	1,085.00
52W Low(₹)	545.50
MCap/Sales	5.49
Beta(1 Month)	-
BV/Share(₹)	148.82

Supriya Lifescience share price insights

Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 11.68% towards employee cost in the year ending Mar 31, 2026. (Source: Standalone Financials)
Supriya Lifescience Share Price Update
Supriya Lifescience Ltd. share price moved up by 4.29% from its previous close of Rs 937.00. Supriya Lifescience Ltd. stock last traded price is 977.15
Share Price Value
Today/Current/Last 977.15973.50
Previous Day 937.00936.15

Found Insights useful?

Supriya Lifescience Share Price Returns

1 Day	4.29%
1 Month	44.59%
3 Months	66.81%
1 Year	39.63%
3 Years	308.25%
5 Years	N.A.

Supriya Lifescience Share Recommendations

Mean recosCurrent

BUY

1 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	-	-	-	-
Buy	1	1	1	1
Hold	-	-	-	-
Sell	-	-	-	-
Strong Sell	-	-	-	-
# Analysts	1	1	1	1

View all Stock Recommendations

News & Analysis

View all Supriya Lifescience Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	209.05	202.56	147.75	187.08	187.75
Total Income Growth (%)	3.21	37.10	-21.03	-0.35	11.34
Total Expenses	141.64	133.83	99.82	122.61	124.66
Total Expenses Growth (%)	5.84	34.06	-18.58	-1.65	17.46
EBIT	67.41	68.73	47.92	64.48	63.09
EBIT Growth (%)	-1.92	43.42	-25.68	2.21	0.95
Profit after Tax (PAT)	49.68	50.43	34.79	50.38	46.78
PAT Growth (%)	-1.49	44.95	-30.95	7.69	1.37
EBIT Margin (%)	32.25	33.93	32.44	34.47	33.60
Net Profit Margin (%)	23.76	24.90	23.55	26.93	24.92
Basic EPS (₹)	6.17	6.27	4.32	6.29	5.82

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	706.30	581.01	470.43	537.63	396.22
Total Revenue Growth (%)	21.57	23.51	-12.50	35.69	23.08
Total Expenses	457.82	415.32	346.94	330.38	228.91
Total Expenses Growth (%)	10.23	19.71	5.01	44.33	1.66
Profit after Tax (PAT)	187.96	119.11	89.86	151.81	123.59
PAT Growth (%)	57.80	32.56	-40.81	22.83	71.28
Operating Profit Margin (%)	35.91	29.41	27.45	39.89	44.47
Net Profit Margin (%)	26.98	20.88	19.49	28.64	32.07
Basic EPS (₹)	23.35	14.80	11.16	18.86	16.89

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 11.68% towards employee cost in the year ending Mar 31, 2026. (Source: Standalone Financials)

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	1,112.31	921.24	820.28	734.76	445.47
Total Assets Growth (%)	20.74	12.31	11.64	64.94	32.89
Total Liabilities	115.55	105.87	120.82	119.07	176.88
Total Liabilities Growth (%)	9.14	-12.37	1.47	-32.68	-4.56
Total Equity	996.76	815.37	699.46	615.69	268.58
Total Equity Growth (%)	22.25	16.57	13.61	129.24	79.18
Current Ratio (x)	5.32	5.17	4.85	4.99	1.82
Total Debt to Equity (x)	0.00	0.00	0.02	0.03	0.25
Contingent Liabilities	4.17	3.46	5.62	5.62	1.57

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020
Net Cash flow from Operating Activities	164.68	113.31	48.80	78.91	66.19
Net Cash used in Investing Activities	-152.24	-173.58	-59.82	-46.80	-133.15
Net Cash flow from Financing Activities	-8.23	-22.36	149.65	-14.52	-3.37
Net Cash Flow	4.20	-82.63	138.63	17.59	-70.33
Closing Cash & Cash Equivalent	79.15	74.96	227.91	92.29	157.58
Closing Cash & Cash Equivalent Growth (%)	5.60	-52.43	146.94	23.54	-30.86
Total Debt/ CFO (x)	0.00	0.00	0.44	0.85	0.25

All figures in Rs Cr, unless mentioned otherwise

Insights

Increase in Cash from Investing
Company has used Rs 176.17 cr for investing activities which is an YoY increase of 15.72%. (Source: Standalone Financials)

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	18.85	14.60	12.84	24.65	46.01
Return on Capital Employed (%)	24.28	19.87	17.47	33.29	57.23
Return on Assets (%)	16.89	12.92	10.95	20.66	27.74
Interest Coverage Ratio (x)	160.50	87.02	44.87	52.78	42.00
Asset Turnover Ratio (x)	0.68	0.66	0.59	0.90	86.50
Price to Earnings (x)	31.45	22.42	17.09	26.18	-
Price to Book (x)	5.92	3.27	2.19	6.44	-
EV/EBITDA (x)	21.52	14.13	10.07	16.97	-
EBITDA Margin (%)	38.85	32.19	30.02	41.80	46.22

Found Financials useful?

Share Price Forecast

Exclusively for ETPrime

REVENUE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
EARNINGS
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
PRICE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP

Technicals

Buy/Sell Signals
No Data Available
Price Analysis
No Data Available
Pivot Levels
R1 - Pivot
-
S1 -
R2 - S2 -
R3 - S3 -
Average True Range
5 Days 14 Days 28 Days
- - -

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Supriya Lifescience	37.61	6.57	17.45	22.42	15.40	21.05	33.47	25.25	25.98	4.40	0.00	0.00
Sequent Scientific	91.30	3.51	6.08	12.55	3.83	33.99	13.52	6.56	4.09	2.38	0.15	1.35
Sun Pharma Adv Res.	4.68	5.42	116.01	112.89	71.54	95.04	85.11	82.65	47.86	2.47	0.42	-2.33
Suven Life Sci	-25.60	11.96	-46.72	-46.54	-44.27	-1.44	-3,881.91	-3,884.12	-12.13	17.69	0.00	0.00
Innova Captab	38.27	4.94	12.91	15.27	7.66	20.29	12.58	8.64	24.63	1.87	0.31	2.94
Add More

Annual Ratios (%)

Choose from Peers

Orchid Pharma
Zota Healthcare
Gujarat Themis
RPG Life Sci
Aarti Drugs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 5,49,67,825 68.30 % 0.00
Pledge 0 0.00 % 0.00
FII 41,51,508 5.16 % -0.02
DII 45,88,032 5.70 % 0.70
MF 10,72,182 1.33 % 0.66
Others 1,67,75,435 20.84 % -0.68
QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 68.30 68.30 68.30 68.30
Pledge 0.00 0.00 0.00 0.00
FII 5.16 5.18 5.46 6.77
DII 5.70 5.00 5.22 4.86
Mutual Funds 1.33 0.67 0.68 0.68
Others 20.84 21.52 21.02 20.07

Mutual Funds Ownership

MF Ownership as on 30 April 2026

Abakkus Flexi Cap Direct-G
Equity: Flexi Cap
- 37.33
  Amount Invested (in Cr.)
- 0.96%
  % of AUM
- 2.42
  % Change (MoM basis)
ITI Large & Mid Cap Direct-G
Equity: Large & MidCap
- 12.71
  Amount Invested (in Cr.)
- 1.72813836%
  % of AUM
- 0.00
  % Change (MoM basis)
Quantum Small Cap Direct-G
Equity: Small Cap
- 7.41
  Amount Invested (in Cr.)
- 3.54%
  % of AUM
- 0.00
  % Change (MoM basis)

View all Mutual Fund Schemes

Supriya Lifescience Top Searches

Corporate Actions

Recent
Final
50%
May 27, 2026
Board Meeting
Audited Results & Final Dividend
May 20, 2026
General Meeting
-
Mar 10, 2026

Announced on	Meeting on
May 20, 2026	May 27, 2026
Audited Results & Final Dividend
Feb 02, 2026	Feb 09, 2026
Quarterly Results
Nov 06, 2025	Nov 12, 2025
Quarterly Results
Aug 06, 2025	Aug 13, 2025
Quarterly Results
May 20, 2025	May 27, 2025
Audited Results & Final Dividend

Dividends
Announced on Ex-Date Dividend%
May 27, 2025 Sep 04, 2025 50%
May 28, 2024 Sep 20, 2024 40%
May 26, 2023 Sep 15, 2023 30%
May 20, 2022 Sep 01, 2022 30%
May 27, 2026 - 50%
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Mar 10, 2026 Apr 11, 2026
-
Sep 02, 2025 Sep 24, 2025
-
Mar 24, 2025 Apr 24, 2025
-
Sep 16, 2024 Sep 27, 2024
Rs.0.8000 per share(40%)Final Dividend & A.G.M.
Jun 26, 2024 Jul 30, 2024
-

About Supriya Lifescience

Supriya Lifescience Ltd., incorporated in the year 2008, is a Small Cap company (having a market cap of Rs 7,864.38 Crore) operating in Pharmaceuticals sector.

Supriya Lifescience Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue and Duty Drawback for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Standalone Total Income of Rs 280.01 Crore, up 33.94 % from last quarter Total Income of Rs 209.05 Crore and up 49.67 % from last year same quarter Total Income of Rs 187.08 Crore. Company has reported net profit after tax of Rs 74.23 Crore in latest quarter.

The company’s top management includes Mr.Satish Waman Wagh, Ms.Saloni Satish Wagh, Ms.Shivani Satish Wagh, Mr.Balasahab Gulabrao Sawant, Ms.Smita Satish Wagh, Mr.Dileep Kumar Jain, Mr.Dinesh Navnitlal Modi, Dr.Ganapati Dadasaheb Yadav, Ms.Neelam Yashpal Arora, Dr.Sunil Subhash Bhagwat, Mr.Krishna Raghunathan, Ms.Prachi Sathe. Company has Kakaria & Associates LLP as its auditors. As on 31-03-2026, the company has a total of 8.05 Crore shares outstanding.

Supriya Lifescience Share Price Today is Rs. 977.15. On previous day, the Supriya Lifescience Share Price (NSE) closed at Rs. 937.0, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 68.3% of the stake in Supriya Lifescience shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Supriya Lifescience stocks was 5.16% as compared to 5.19% in Dec 2025 with decrease of 0.03%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 5.7% as compared to 5.0% in Dec 2025 with increase of 0.7%. Out of the total DII holdings in Supriya Lifescience shares 1.33% was held by mutual funds. The rest including public held is 20.84%. Supriya Lifescience stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Supriya Lifescience Dividend: Ever since 2008, Supriya Lifescience dividends has been paid out around 5 times. As on 12 Jun, 2026, 03:56 PM IST, The overall dividend yield for Supriya Lifescience stands at 0.0%. The last dividend paid was on September 4, 2025 (Rs. 1.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 25.98.

Supriya Lifescience Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 280.01 Cr. of sales and 33.94% of quarterly net profit, there have been multiple ups and downs in the Supriya Lifescience stock prices in the past few weeks. For example, Supriya Lifescience stock price on 5th of June 2026 was around Rs. 947.95. Supriya Lifescience share price now stands at an average of Rs. 977.15. Judging by last week's performance, stock is in down trend.

Supriya Lifescience has a median target price of Rs. 850.0 in 12 months by 1 analysts. They have provided a high estimate of Rs. 850.0 and low estimate of Rs. 850.0 for Supriya Lifescience share.

Historical Prices and Performance:
Supriya Lifescience, incorporated in 2008 is a Mid Cap company (with a market cap of Rs. 7864.38) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Supriya Lifescience stock was 17.45%, 18.85%, 14.6%, 12.84% and 24.65% respectively.
The Supriya Lifescience share gave a 3 year return of 308.25% as compared to Nifty 50 which gave a return of 26.99%.
Supriya Lifescience announced 50.0% final dividend on September 4, 2025.

Key Metrics:
PE Ratio of Supriya Lifescience is 37.61
Prices/Sales Ratio of Supriya Lifescience is 5.49
Price/Book Ratio of Supriya Lifescience is 6.57

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Supriya Lifescience, major competitors and peers include Sequent Scientific, Sun Pharma Adv Res., Suven Life Sci and Innova Captab. As of Dec 2025, the dividend yield of Supriya Lifescience stands at 0.0% while Sequent Scientific, Sun Pharma Adv Res., Suven Life Sci and Innova Captab stand at 0.0%, 0.0%, 0.0% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 37.61 and 6.57 respectively.

Leadership of Supriya Lifescience :
Prachi Sathe is Co. Secretary & Compl. Officer
Krishna Raghunathan is Chief Financial Officer
Satish Waman Wagh is Chairman & Executive Director
Saloni Satish Wagh is Managing Director
Shivani Satish Wagh is Joint Managing Director
Smita Satish Wagh is Whole Time Director
Balasahab Gulabrao Sawant is Whole Time Director
Dileep Kumar Jain is Ind. Non-Executive Director
Dinesh Navnitlal Modi is Ind. Non-Executive Director
Neelam Yashpal Arora is Ind. Non-Executive Director
Ganapati Dadasaheb Yadav is Ind. Non-Executive Director
Sunil Subhash Bhagwat is Ind. Non-Executive Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

BSE SmallCap, BSE Healthcare, BSE AllCap, Nifty Smallcap 500, Nifty Microcap 250

Address

207/208, Udyog Bhavan,Sonawala Road,Mumbai, Maharashtra - 400063

Contact

supriya@supriyalifescience.com

http://www.supriyalifescience.com

Executive Leadership

SW

Satish Waman Wagh

Chairman & Executive Director

SS

Saloni Satish Wagh

Managing Director

SS

Shivani Satish Wagh

Joint Managing Director

BG

Balasahab Gulabrao Sawant

Whole Time Director

Show More

Auditors

Kakaria & Associates LLP

FAQs about Supriya Lifescience share

1. What is Supriya Lifescience share price and what are the returns for Supriya Lifescience share?
Supriya Lifescience share price is Rs 977.15 as on 12 Jun, 2026, 03:56 PM IST. Supriya Lifescience share price is up by 4.29% based on previous share price of Rs 952.4. Supriya Lifescience share price trend:
- Last 12 Months: Supriya Lifescience share price moved up 39.63%
- Last 3 Years: Supriya Lifescience Share price moved up by 308.25%
2. What are the returns for Supriya Lifescience share?
Return Performance of Supriya Lifescience Shares:
- 1 Week: Supriya Lifescience share price moved up by 3.08%
3. What's the market capitalization of Supriya Lifescience?
Market Capitalization of Supriya Lifescience stock is Rs 7,864.38 Cr.
4. What is Supriya Lifescience's 52 week high / low?
52 Week high of Supriya Lifescience share is Rs 1,085.00 while 52 week low is Rs 545.50
5. What is the PE & PB ratio of Supriya Lifescience?
The PE ratio of Supriya Lifescience stands at 36.06, while the PB ratio is 6.3.

Top Gainers

As on 04:06 PM | 12 Jun 2026

1,028.70

714.90 (227.82%)

Netweb Technologies

4,587.40

2780.60 (153.90%)

Syrma SGS Technology

1,266.70

737.70 (139.45%)

14.90

8.12 (119.76%)

4,942.50

2633.90 (114.09%)

Top Losers

As on 03:58 PM | 12 Jun 2026

Tata Investment

665.90

-6218.10 (-90.33%)

339.50

-2678.10 (-88.75%)

757.55

-3315.15 (-81.40%)

403.30

-1723.50 (-81.04%)

Authum Investment

530.15

-1967.65 (-78.78%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.